20 completed, 3 unknown, 1 not yet recruiting. 17 Phase 3, 2 Phase 1, 2 Phase 2, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 17 | Completed 13, Unknown 3, Not yet recruiting 1 |
| Phase 1 | 2 | Completed 2 |
| Phase 2 | 2 | Completed 1, Unknown 1 |
| Not applicable | 1 | Completed 1 |
Follow Cinnagen: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of the Efficacy and Safety of Tirzepatide, a Dual GLP-1/GIP Agonist, on Functional Capacity in Reduced Ejection Fraction Heart Failure Patients With Obesity Tirzepatide, Placebo - Heart Failure and Reduced Ejection Fraction, Obesity & Overweight | Phase 3 | Not yet recruiting | Shahid Beheshti University of Medical Sciences | 60 | 2026-07-18 | 2026-08-03 |
| Spartina® (Tirzepatide) Effectiveness and Safety Evaluation Obesity & Overweight | Completed | Cinnagen | 175 | 2025-11-11 | 2026-07-15 | |
| Efficacy and Safety of YW17 (Laronidase-CinnaGen) Compared to Aldurazyme® in MPS I Patients Laronidase, Antihistamine, Antipyretic - Mucopolysaccharidosis Type 1 | Phase 3 | Completed | Cinnagen | 12 | 2022-09-10 | 2024-08-06 |
| Booster Study of SpikoGen COVID-19 Vaccine SpikoGen vaccine - COVID-19 | Phase 3 | Completed | Vaxine Pty Ltd | 81 | 2022-09-07 | 2025-09-17 |
| Australian Phase 2b Study to Assess Effect of Dose Interval on Spikogen Covid-19 Vaccine Spikogen/Covax-19 - COVID-19 | Phase 2 / Phase 3 | Unknown | Vaxine Pty Ltd | 200 | 2022-03-01 | 2024-08-07 |
| Immunogenicity and Safety of the SpikoGen COVID-19 Vaccine in Children Aged 5 to <12 Years and 12 to <18 Years Compared With Adults Aged 18 to 40 Years Low-dose SARS-CoV-2 recombinant spike protein + Advax-SM adjuvant, SARS-CoV-2 recombinant spike protein + Advax-SM adjuvant - COVID-19 | Phase 3 | Completed | Cinnagen | 581 | 2022-02-23 | 2022-10-17 |
| Immunogenicity and Safety of a Booster Dose of the SpikoGen Vaccine in Kidney Transplant Recipients After Two Doses of Sinopharm Vaccine SARS-CoV-2 recombinant spike protein + Advax-SM adjuvant - COVID-19 | Not applicable | Completed | Cinnagen | 43 | 2022-02-04 | 2023-08-31 |
| Immunogenicity and Safety of a Booster Dose of the SpikoGen COVID-19 Vaccine SARS-CoV-2 recombinant spike protein + Advax-SM adjuvant, Saline placebo - COVID-19 | Phase 3 | Completed | Cinnagen | 300 | 2021-12-15 | 2022-10-14 |
| Phase III Clinical Trial of CinnaGen COVID-19 Vaccine (SpikoGen) SARS-CoV-2 recombinant spike protein + Advax-SM adjuvant, Saline placebo - Covid19 | Phase 3 | Completed | Cinnagen | 16876 | 2021-08-07 | 2022-10-13 |
| Phase II Clinical Trial of CinnaGen COVID-19 Vaccine (SpikoGen) SARS-CoV-2 recombinant spike protein + Advax-SM adjuvant, Saline placebo - Covid19 | Phase 2 | Completed | Cinnagen | 400 | 2021-05-30 | 2022-10-13 |
| Efficacy and Safety of Zerafil® (Omalizumab) in Participants With Uncontrolled Moderate to Severe Allergic Asthma Omalizumab (CinnaGen), Omalizumab (Genentech, Inc., USA and Novartis Pharmaceuticals Corp, Switzerland) - Allergic Asthma, Uncontrolled Moderate to Severe | Phase 3 | Completed | Cinnagen | 256 | 2021-01-18 | 2023-04-14 |
| Efficacy and Safety of Aflibercept in Patients With Neovascular Age-related Macular Degeneration Aflibercept (CinnaGen Co, Iran), Aflibercept (Regeneron, USA) - Age-Related Macular Degeneration, Neovascular Age-related Macular Degeneration | Phase 3 | Completed | Cinnagen | 168 | 2019-10-01 | 2023-02-14 |
| Efficacy and Safety of Xacrel® (Ocrelizumab) in Participants With Relapsing Remitting Multiple Sclerosis Ocrelizumab (CinnaGen, Iran), Ocrelizumab (Roche, Switzerland) - Multiple Sclerosis, Relapsing-Remitting | Phase 3 | Completed | Cinnagen | 170 | 2019-08-19 | 2022-10-18 |
| Comparing Efficacy and Safety of CinnaGen-liraglutide Versus Victoza® in Patients With Type II Diabetes Liraglutide 6 MG/ML Pen Injector, Metformin, Sulfonylurea/non-sulfonylurea insulin secretagogues - Diabetes Mellitus, Type 2 | Phase 3 | Unknown | Cinnagen | 300 | 2019-06-20 | 2019-02-06 |
| Comparing Efficacy and Safety Between Pertuzumab® and Perjeta® in Neoadjuvant Treatment of HER2+ Breast Cancer Trastuzumab, Pertuzumab, Carboplatin - HER2-positive Breast Cancer | Phase 3 | Completed | Cinnagen | 214 | 2018-08-11 | 2024-07-26 |
| Comparing Efficacy and Safety of Cetuximab (CinnaGen) Versus Erbitux® (Merck) in Metastatic Colorectal Cancer Cetuximab + FOLFIRI - Metastatic Colorectal Cancer | Phase 3 | Unknown | Cinnagen | 234 | 2018-01-20 | 2023-04-05 |
| Efficacy and Safety of Peginterferon Beta-1a (CinnaGen) in Participants With Relapsing Remitting Multiple Sclerosis Pegylated interferon beta-1a, Interferon Beta-1A Prefilled Syringe - Relapsing Remitting Multiple Sclerosis (RRMS) | Phase 3 | Completed | Cinnagen | 168 | 2017-12-20 | 2022-10-18 |
| Pharmacokinetics and Pharmacodynamics of CinnoVex (Interferon Beta-1a) Compared to Avonex (Interferon Beta-1a) Interferon Beta-1A - Bioequivalence, Healthy | Phase 1 | Completed | Cinnagen | 40 | 2017-11-27 | 2020-01-10 |
| A Study Of CinnoRA (Adalimumab-CinnaGen) And Adalimumab (Humira) In Healthy Subjects Adalimumab - Bioequivalence, Phase 1 | Phase 1 | Completed | Cinnagen | 74 | 2016-10-22 | 2018-09-19 |
| Comparing Efficacy and Safety of CinnaGen Beta Erythropoietin (CinnaPoietin®) Versus Eprex® on the Treatment of Anemia in ESRD Hemodialysis Patients CinnaPoietin®, Eprex®, Nephrovit - Anemia in End-Stage Renal Disease | Phase 3 | Completed | Cinnagen | 156 | 2016-06-22 | 2019-12-18 |
Showing 20 of 24. Sign in to see all of them.
COVID-19 (7) · Multiple Sclerosis (2) · Obesity (2) · Overweight (2) · Anemia (1) · Asthma (1) · Colorectal Neoplasms (1) · Coronavirus Infections (1) · Diabetes Mellitus, Type 2 (1) · Febrile Neutropenia (1) · Heart Failure, Systolic (1) · Kidney Failure, Chronic (1) · Macular Degeneration (1) · Mucopolysaccharidosis I (1) · Multiple Sclerosis, Relapsing-Remitting (1)
SARS-CoV-2 recombinant spike protein with delta inulin and CpG-ODN adjuvant vaccine (7) · Adalimumab (2) · Saline Solution (2) · Antipyretics (1) · Carboplatin (1) · Cetuximab (1) · Docetaxel (1) · Epoetin Alfa (1) · Fluorouracil (1) · Folic Acid (1) · Glatiramer Acetate (1) · Growth Hormone (1) · Histamine Antagonists (1) · Iduronidase (1) · Interferon beta-1a (1)
Iran (16) · Australia (2) · Finland (1)
Payam Tabarsi, M.D. (4) · Abdorreza Naser Moghadasi, Assistant Professor (1) · Ahmadreza Jamshidi, Professor (1) · Ali Rabani, Professor (1) · Arash Jenabian, Professor (1) · Behrouz Najafi, MD (1) · Dimitar Sajkov, MD, PhD (1) · Dimitar Sajkov, MD/PhD (1) · Esmaeil Idani, Pulmonologist (1) · Mika Scheinin, MD, PhD (1) · Mohammad Ali Sahraian, professor (1) · Mohammad Ebrahim Khamseh, Professor (1) · Mohsen Nafar, M.D. (1) · Nikolai Petrovsky, MD/PhD (1) · Somayeh Amini, PharmD (1)
PMID 39914274, PMID 28728599, PMID 30253403, PMID 31985294, PMID 35436611, PMID 35758850, PMID 35792924, PMID 36096430, PMID 37707701, PMID 39136011, PMID 39217809, PMID 39438591, PMID 40830667
2016 (1)